Classifications

• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
  • A01N37/10—Aromatic or araliphatic carboxylic acids, or thio analogues thereof; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
  • A01N25/30—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
  • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
  • A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
  • A01N43/14—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom six-membered rings
  • A01N43/16—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom six-membered rings with oxygen as the ring hetero atom
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N61/00—Biocides, pest repellants or attractants, or plant growth regulators containing substances of unknown or undetermined composition, e.g. substances characterised only by the mode of action
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
  • A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
  • C08F20/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
  • C08F20/02—Monocarboxylic acids having less than ten carbon atoms, Derivatives thereof
  • C08F20/04—Acids, Metal salts or ammonium salts thereof
  • C08F20/06—Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
  • C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
  • C08L33/02—Homopolymers or copolymers of acids; Metal or ammonium salts thereof

Definitions

• the present invention relates to a virus infection inhibiting agent, a resin composition, a masterbatch for synthetic resin molding, and a virus infection inhibiting product.
• the highly pathogenic avian influenza virus has mutated and has been confirmed to infect humans, and there is also concern about the Sars virus, which has an extremely high mortality rate, and anxiety about the virus is only increasing.
• Patent Document 1 proposes an antiviral synthetic resin composition containing 0.5 parts by weight or more of a sulfonic acid surfactant per 100 parts by weight of the synthetic resin.
• the antiviral synthetic resin composition has a problem in that it has low water resistance and its antiviral properties (viral infection inhibiting effect) are reduced after wiping with water.
• the present invention provides a virus infection inhibitor that can maintain an excellent virus infection inhibiting effect even after wiping with water.
• the present invention provides a resin composition, a masterbatch for synthetic resin molding, and a virus infection inhibiting product using the above virus infection inhibiting agent.
• the virus infection inhibitor of the present invention contains an organic acid (A) having a solubility in water at 25°C of 0.4 g/L or less.
• the resin composition of the present invention is characterized by containing a synthetic resin and the above-mentioned virus infection inhibitor.
• the synthetic resin molding masterbatch of the present invention is characterized by containing a synthetic resin and the virus infection inhibitor described above.
• the virus infection inhibiting product of the present invention is characterized by containing a base material and the virus infection inhibiting agent.
• the virus infection inhibitor of the present invention contains an organic acid (A) having a water solubility of 0.4 g/L or less in water at 25°C, it is possible to maintain an excellent virus infection inhibiting effect even after wiping with water. can.
• A organic acid
• the virus infection inhibitor of the present invention contains as an active ingredient an organic acid (A) having a solubility in water at 25°C of 0.4 g/L or less.
• the virus infection inhibitor contains, as an active ingredient, an organic acid (A) having a solubility in water at 25°C of 0.4 g/L or less (hereinafter sometimes simply referred to as "organic acid (A)"). There is.
• the virus infection inhibitor contains as an active ingredient an organic acid (A) with a solubility in water at 25°C of 0.4 g/L or less, the virus infection inhibitor remains in place even after wiping with water. It can remain in a good condition and continuously exhibit excellent virus infection prevention effects.
• A organic acid
• the organic acid (A) only needs to have a solubility in water at 25° C. of 0.4 g/L or less, and may be a polymer.
• the above functional groups in the organic acid (A) may be one or more.
• the organic acid (A) preferably has a carboxy group or a sulfo group, and preferably has a carboxy group, since this can further improve the effect of inhibiting virus infection against enveloped viruses and non-enveloped viruses. More preferred.
• alginic acid (solubility: 0 g/L), lauric acid (solubility: 0 g/L) ), sebacic acid (solubility: 0.25 g/L), dodecanedioic acid (solubility: 0 g/L), isophthalic acid (solubility: 0.13 g/L), terephthalic acid (solubility: 0.017 g/L), methylene Disalicylic acid (solubility: 0g/L), cis- ⁇ 4-tetrahydrophthalic acid (solubility: 0g/L), pelargonic acid (solubility: 0.28g/L), capric acid (solubility: 0.15g/L), laurin Acid (Solubility: 0.0048g/L), Myristic Acid (Solubility: 0g/L), Palmitic Acid (Solubility: 0g/L), Stearic Acid (Solubility: 0g/L),
• the organic acid (A) is a polymer
• the organic acid (A) has a carboxy group (-COOH), a sulfo group (-SO 3 H), a phosphonic acid group in the side chain of the linear polymer.
• a polymer having a carboxy group or a sulfo group is preferable because the virus infection inhibitor exhibits an excellent virus infection inhibiting effect.
• the linear polymer is not particularly limited, and for example, vinyl polymers, polyesters, and polyurethanes are preferable, and vinyl polymers are preferable.
• Carboxy group (-COOH), sulfo group (-SO 3 H), phosphonic acid group [-P( O)(OH) 2 ] or phosphoric acid group [-OPO(OH)] in the side chain of the linear polymer.
• the polymer having [ -P Examples thereof include a polymer containing a monomer component having a phosphoric acid group [-OPO(OH) 2 ], and a polymer containing a monomer component having a phosphoric acid group [-OPO(OH) 2 ].
• Examples of monomers having a carboxyl group include acrylic acid, methacrylic acid, acrylic acid, methacrylic acid, ⁇ -carboxyethyl (meth)acrylate, 5-carboxypentyl (meth)acrylate, and mono(meth)acryloyloxysuccinate.
• Examples include ethyl ester, ⁇ -carboxypolycaprolactone mono(meth)acrylate, crotonic acid, maleic acid, fumaric acid, itaconic acid, citraconic acid, carboxybetaine type monomers, and acrylic acid and methacrylic acid are preferred.
• the monomer having a carboxy group may be used alone or in combination of two or more types.
• Examples of monomers having a sulfo group include p-styrenesulfonic acid, m-styrenesulfonic acid, o-styrenesulfonic acid, acrylamide t-butylsulfonic acid, vinylsulfonic acid, and 2-(methacryloyloxy)ethanesulfonic acid. , 3-(methacryloyloxy)propanesulfonic acid, 4-[(3-methacrylamidopropyl)dimethylammonio]butane-1-sulfonic acid, and the like.
• the monomer having a sulfo group may be used alone or in combination of two or more kinds.
• Examples of the monomer having a phosphonic acid group include vinylphosphonic acid and alkyl vinylphosphonate.
• the monomer having a phosphonic acid group may be used alone or in combination of two or more types.
• Examples of the monomer having a phosphoric acid group include phosphoric acid monoacrylate, phosphoric acid diacrylate, phosphoric acid monomethacrylate, phosphoric acid dimethacrylate, phosphoric acid methacrylic acid 2-hydroxyethyl ester, and the like.
• the monomer having a phosphoric acid group may be used alone or in combination of two or more kinds.
• the total content of monomer components having an acid group [-OPO(OH) 2 ] is preferably 50% by mass or more, more preferably 60% by mass or more, since the virus infection inhibiting effect of the virus infection inhibitor improves. , more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, more preferably 99% by mass or more, and more preferably 100% by mass.
• Examples of the copolymerizable monomer include alkyl acrylate, alkyl methacrylate, vinyl alkyl ether, vinyl acetate, ethylene, propylene, butylene, butadiene, diisobutylene, vinyl chloride, vinylidene chloride, 2-vinylnaphthalene, styrene, Examples include acrylonitrile, sodium acrylate, acrylamide, methacrylamide, diacetone acrylamide, vinyltoluene, vinylpyridine, methyl methacrylate, sodium methacrylate, and hydroxyethyl methacrylate.
• the solubility of the organic acid (A) in water at 25°C is 0.4 g/L or less, preferably 0.3 g/L or less, more preferably 0.2 g/L or less, and more preferably 0.15 g/L or less. preferable. Since the solubility of the organic acid (A) in water at 25°C is 0.4 g/L or less, the virus infection inhibitor exhibits excellent water resistance and maintains an excellent virus infection inhibiting effect even after wiping with water. can be maintained.
• the organic acid (A) has improved compatibility with the synthetic resin, and the virus infection inhibitor can be uniformly dispersed in the synthetic resin, and the carboxy group (-COOH) in the organic acid (A),
• the effectiveness of the agent in inhibiting viral infection is improved.
• the solubility of the organic acid (A) in water at 25°C is preferably 0.001 g/L or more, more preferably 0.01 g/L or more.
• the solubility of the organic acid (A) in water at 25° C. is 0.001 g/L or more, the interaction between the organic acid (A) and the polar group of the virus is improved, and the effect of inhibiting virus infection is improved.
• the solubility of the sodium salt of the organic acid (A) in water at 25° C. is preferably 0.3 g/L or more, more preferably 0.5 g/L or more, and even more preferably 1 g/L or more.
• the upper limit of the solubility of the sodium salt of the organic acid (A) in water at 25° C. is not particularly limited.
• the solubility of the sodium salt of the organic acid (A) in water at 25° C. is preferably, for example, 1000 g/L or less.
• the surface of the virus infection prevention product described below is sometimes disinfected with an aqueous sodium hypochlorite solution, but in this case, a portion of the organic acid (A) ionically bonds with the sodium hypochlorite to form the organic acid (A).
• the solubility of the sodium salt of the organic acid (A) in water at 25°C is 0.3 g/L or more, the sodium salt of the organic acid (A) is converted into a sodium hypochlorite aqueous solution.
• the organic acid (A) that has not been converted into a sodium salt can be immediately dissolved and removed, and the excellent virus infection inhibiting effect of the virus infection inhibitor can be maintained by effectively exposing the organic acid (A) that has not been converted into a sodium salt.
• the solubility of an organic acid in water at 25°C refers to the mass of the organic acid dissolved in 1 L of water at 25°C. That is, the solubility of an organic acid in water at 25°C refers to the mass of the organic acid in a saturated solution (25°C) containing 1 L of water.
• the solubility of organic acids in water at 25°C is determined by the OECD Chemical Test Guideline No. 105 (water solubility), measured at 25°C.
• the solubility of a sodium salt of an organic acid in water at 25°C refers to the mass of the sodium salt of an organic acid that dissolves in 1 L of water at 25°C. That is, the solubility of a sodium salt of an organic acid in water at 25°C refers to the mass of the sodium salt of an organic acid in a saturated solution (25°C) containing 1 L of water.
• the solubility of sodium salts of organic acids in water at 25°C is determined by OECD Chemical Test Guidelines No. 105 (water solubility), measured at 25°C.
• the pKa1 of the organic acid (A) at 25°C is more preferably 4.6 or less, more preferably 3.8 or less.
• the interaction with the polar group of the virus improves, and the virus infection inhibiting effect of the virus infection inhibitor improves.
• the acid dissociation constant Ka is defined by the equation (2), and pKa is the acid dissociation constant Ka. It is defined as the common logarithm (3) of the reciprocal of the constant Ka.
• ionization of the polyvalent acid proceeds in multiple stages, and pKa1 refers to pKa calculated based on the ionization constant of the first stage.
• pKa1 of an organic acid at 25°C refers to a value measured by titration. Specifically, titration is performed at 25°C using an organic acid and sodium hydroxide, and the pH at 25°C is measured at the half-equivalence point (the point at which half of the amount that completes neutralization is dropped). Then, pKa1 can be determined.
• the organic acid (A) is a polymer
• the solubility of the organic acid (A) in water at 25° C. can be lowered, the virus infection inhibitor exhibits excellent water resistance, and the excellent virus infection inhibiting effect can be maintained even after wiping with water.
• the organic acid (A) has improved compatibility with the synthetic resin, and the virus infection inhibitor can be uniformly dispersed in the synthetic resin, and the carboxy group (-COOH) in the organic acid (A),
• the effectiveness of the agent in inhibiting viral infection is improved.
• the method for crosslinking the polymer is not particularly limited, and may be carried out in a commonly used manner.
• a method for crosslinking a polymer for example, (1) after polymerizing monomers to obtain a polymer, crosslinking the polymer by supplying a crosslinking aid and a peroxide to the polymer and heating it; and (2) a method in which monomers are polymerized to obtain a polymer, and then a crosslinking agent is supplied to the polymer and heated to crosslink the polymer.
• the crosslinking aid is not particularly limited, and examples thereof include divinylbenzene, trimethylolpropane trimethacrylate, 1,9-nonanediol dimethacrylate, 1,10-decanediol dimethacrylate, trimellitic acid triallyl ester, and triallylisocyanate.
• the crosslinking aids may be used alone or in combination of two or more.
• the peroxide is not particularly limited, and examples thereof include 2,4-dichlorobenzoyl peroxide, benzoyl peroxide, t-butyl perbenzoate, cumyl hydroperoxide, t-butyl hydroperoxide, and 1,1-dichlorobenzoyl peroxide.
• the crosslinking agent is not particularly limited, and general-purpose crosslinking agents can be used, such as epoxy crosslinking agents, isocyanate crosslinking agents, imine crosslinking agents, and the like. Note that the crosslinking agents may be used alone or in combination of two or more.
• isocyanate-based crosslinking agent examples include tolylene diisocyanate, naphthylene-1,5-diisocyanate, hexamethylene diisocyanate, diphenylmethane diisocyanate, xylylene diisocyanate, and trimethylolpropane-modified tolylene diisocyanate.
• epoxy crosslinking agent examples include N,N'-(cyclohexane-1,3-diylbismethylene)bis(diglycidylamine), N,N,N',N'-tetraglycidyl-1,3-benzenedi (Methanamine) and the like are preferred.
• the gel fraction of the organic acid (A) is preferably 65% by mass or more, more preferably 70% by mass or more, and even more preferably 75% by mass or more.
• the gel fraction of the organic acid (A) is preferably 99% by mass or less, more preferably 97% by mass or less, and even more preferably 96% by mass or less.
• the gel fraction of the organic acid (A) refers to a value measured in the following manner.
• the organic acid (A) was weighed with Ag, immersed in purified water at 60°C for 24 hours, the insoluble matter was filtered through a 200-mesh wire mesh, and the residue on the wire mesh was vacuum-dried at 80°C for 16 hours. The weight of the dried residue is measured (Bg), and the gel fraction of the organic acid (A) is calculated using the following formula.
• Gel fraction (mass%) of organic acid (A) (B/A) x 100
• the organic acid (A) is preferably solid at 1 atm (1013.25 hPa) and 25°C. If the organic acid (A) is solid at 1 atm and 25°C, it will easily appear on the surface of processed coatings and other virus infection prevention products, making it easier to come into contact with viruses and improving the virus infection prevention effect. .
• the virus infection inhibitor contains an organic acid (B) (hereinafter sometimes simply referred to as "organic acid (B)”) with a solubility in water of 25°C exceeding 0.4 g/L as an active ingredient. Good too.
• organic acid (B) organic acid
• the virus infection inhibitor can immediately exhibit the effect of inhibiting virus infection, and can inhibit virus infection with immediate effect on substrates, etc. Effects can be added.
• a base material such as a coating film contains a virus infection inhibiting agent, even when the base material is thick, an excellent virus infection inhibiting effect can be imparted to the virus infection inhibiting product.
• the organic acid (B) only needs to have a solubility in water at 25°C of more than 0.4 g/L.
• the organic acid (B) preferably has a carboxy group or a sulfo group, and preferably has a carboxy group, since this can further improve the effect of inhibiting virus infection against enveloped viruses and non-enveloped viruses. is more preferable.
• the solubility of the organic acid (B) in water at 25° C. exceeds 0.4 g/L, preferably 1 g/L or more, more preferably 2 g/L or more, and even more preferably 3 g/L or more.
• the solubility of the organic acid (B) in water at 25°C exceeds 0.4 g/L, the viral infection inhibiting effect of the virus infection inhibitor can be immediately expressed, and the virus has immediate effect on substrates, etc. It can provide an infection prevention effect.
• a base material such as a coating film contains a virus infection inhibiting agent
• a virus infection inhibiting agent even when the base material is thick, an excellent virus infection inhibiting effect can be imparted to the virus infection inhibiting product.
• the virus infection inhibitor contains a compound having an organic acid (A), an organic acid (B), and a salt of a sulfo group, the product can be used as a virus infection prevention product even if the base material is thick. It is possible to more effectively impart an excellent virus infection prevention effect to.
• the organic acid (B) has relatively high hydrophilicity, and the surface of the base material containing the virus infection inhibitor, especially the base material containing synthetic resin.
• a base material that is easily exposed to virus infection and contains a virus infection inhibitor (virus infection prevention product) immediately exhibits a virus infection inhibition effect.
• Organic acids (B) are easily exposed on the surface of substrates containing virus infection inhibitors, especially substrates containing synthetic resins, so even if the substrate is thick, It can provide the effect of inhibiting viral infection.
• the solubility of the organic acid (B) in water at 25°C is preferably 20 g/L or less, more preferably 18 g/L or less, more preferably 16 g/L or less, more preferably 14 g/L or less, and 12 g/L or less. is more preferable, and 10 g/L or less is more preferable.
• solubility of the organic acid (B) in water at 25°C is 20 g/L or less, discoloration of the surface of the base material containing the virus infection inhibitor can be reduced, and the excellent appearance of the base material can be maintained. It's easy to do.
• the solubility of the sodium salt of the organic acid (B) in water at 25° C. is preferably 1 g/L or more, more preferably 2 g/L or more, and even more preferably 3 g/L or more.
• the upper limit of the solubility of the sodium salt of the organic acid (B) in water at 25° C. is not particularly limited.
• the solubility of the sodium salt of the organic acid (B) in water at 25° C. is preferably, for example, 800 g/L or less.
• the surface of the virus infection prevention product described below is sometimes disinfected with an aqueous sodium hypochlorite solution, but in this case, a portion of the organic acid (B) ionically bonds with the sodium hypochlorite to form the organic acid (B).
• the sodium salt of the organic acid (B) is produced in an aqueous sodium hypochlorite solution. It can be immediately dissolved and removed, effectively exposing the organic acid (B) that is not converted into a sodium salt, and maintaining the excellent virus infection inhibiting effect of the virus infection inhibitor.
• the pKa1 of the organic acid (B) at 25° C. is more preferably 4.6 or less, more preferably 4.3 or less.
• the interaction with the polar group of the virus is improved, and the virus infection inhibiting effect of the virus infection inhibitor is improved.
• the organic acid (B) is preferably solid at 1 atm (1013.25 hPa) and 25°C. If the organic acid (B) is solid at 1 atm and 25°C, it will easily appear on the surface of processed coatings and other virus infection prevention products, making it easier to come into contact with viruses and improving the virus infection prevention effect. .
• the virus infection inhibitor further contains a compound having a salt of a sulfo group as an active ingredient.
• a compound having a salt of a sulfo group has a salt of a sulfo group (-SO 3 H) in the molecule.
• a compound having a salt of a sulfo group is derived from a molecular structure containing a salt of a sulfo group ( -SO 3 Demonstrates the effect of inhibiting viral infection.
• Compounds having a salt of a sulfo group have particularly excellent virus infection inhibiting effects against enveloped viruses.
• the virus infection inhibitor contains a compound having an organic acid (B) and a salt of a sulfo group
• the virus infection prevention product will have excellent virus infection prevention properties even if the base material is thick. Effects can be applied more effectively.
• the salt of the sulfonic acid group is not particularly limited, and includes, for example, sodium salt (-SO 3 Na), calcium salt [(-SO 3 - ) 2 Ca 2+ ], ammonium salt (-SO 3 - NH 4 + ), magnesium salt [(-SO 3 - ) 2 Mg 2+ ], barium salt [(-SO 3 - ) 2 Ba 2+ ], etc., and sodium salt (-SO 3 Na) is preferable.
• the compound having a salt of a sulfo group is preferably an organic compound.
• an organic compound refers to a compound containing at least one (preferably two or more) carbon atoms and carbon-hydrogen bonds (C--H bonds) in the molecule.
• the affinity with the organic acid (A) and the organic acid (B) improves, and the compound having a salt of a sulfo group with the organic acid (A) and the organic acid ( B), the interaction between the compound having a salt of a sulfo group and the organic acid (A) and the organic acid (B) is improved, and viruses that do not have an envelope (non-enveloped virus) and viruses that have an envelope (enveloped viruses) and the virus infection prevention effect against both.
• the compound having a salt of a sulfo group preferably has an aromatic ring.
• the affinity with the organic acid (A) and the organic acid (B) improves, and the compound having a salt of a sulfo group with the organic acid (A) and the organic acid (B) improves.
• the organic acid (B) is brought closer to the compound, and the interaction between the compound having a salt of a sulfo group and the organic acid (A) and the organic acid (B) is improved, thereby inhibiting virus infection against both enveloped and non-enveloped viruses. Improves effectiveness.
• the aromatic ring may be a monocyclic aromatic ring or a complex of monocyclic aromatic rings condensed (fused aromatic ring).
• the aromatic ring is not particularly limited, and includes, for example, a benzene ring, a naphthalene ring, an anthracene ring, biphenyl, phenoxyphenyl, and the like, with benzene rings and naphthalene rings being preferred.
• the aromatic ring has one or more hydrogen atoms removed from either a monocyclic aromatic ring or a fused aromatic ring, and is bonded to another atom through a covalent bond.
• the sulfo group salt is preferably bonded directly or indirectly to the aromatic ring, and more preferably directly bonded to the aromatic ring. Due to the affinity between the aromatic ring of the compound having a salt of a sulfo group and the organic acid (A) and the organic acid (B), the compound having a salt of a sulfo group and the organic acid (A) and the organic acid (B) become close to each other.
• the sulfo group salt when the sulfo group salt is indirectly bonded to an aromatic ring, the sulfo group salt is an alkylene group having 1 to 4 carbon atoms (preferably a methylene group or an ethylene group). ) is preferably bonded to the aromatic ring. While maintaining the affinity between the aromatic ring in the compound having a sulfo group salt and the organic acid (A) and the organic acid (B), the sulfo group salt is appropriately separated from the aromatic ring due to the alkylene group. In this way, the sulfo group salt can be oriented in a more exposed state, and the virus infection inhibitor exhibits an excellent virus infection inhibiting effect.
• alkylene groups having 1 to 4 carbon atoms include methylene group [-CH 2 -], ethylene group [-CH 2 -CH 2 -], propylene group [-CH(CH 3 )-CH 2 - ], trimethylene group [-CH 2 --CH 2 --CH 2 --], butylene group, and the like.
• Compounds having a salt of a sulfo group are not particularly limited as long as they have one or more salts of a sulfo group in the molecule, and examples include linear alkylbenzene sulfonates, ⁇ -olefin sulfonates, alkyl Examples include diphenyl ether sulfonate, polyoxyalkylene alkyl ether sulfate, and linear polymer having a sulfo group salt in the side chain.
• the compound having a salt of a sulfo group has the action of a surfactant.
• the organic acid (A) and organic acid (B) in the virus infection inhibitor can easily exist outside.
• the organic acid (A) and organic acid (B) can be easily segregated, and the water resistance of the virus infection prevention product (molded article) can be further improved.
• Examples of compounds having a salt of a sulfo group having the action of a surfactant include linear alkylbenzene sulfonates, ⁇ -olefin sulfonates, alkyldiphenyl ether sulfonates, and polyoxyalkylene alkyl ether sulfate salts. Examples include.
• the action of a surfactant is an action that adsorbs or arranges at the interface between gas-liquid, gas-solid, liquid-solid, liquid-liquid, or liquid-solid and significantly changes the properties of the interface or surface. say.
• linear alkylbenzenesulfonates include sodium dodecylbenzenesulfonate, calcium dodecylbenzenesulfonate, ammonium dodecylbenzenesulfonate, magnesium dodecylbenzenesulfonate, barium dodecylbenzenesulfonate, sodium tridecylbenzenesulfonate, and tridecylbenzenesulfonate.
• Examples include ammonium benzenesulfonate, sodium tetradecylbenzenesulfonate, ammonium tetradecylbenzenesulfonate, and sodium dodecylbenzenesulfonate is preferred.
• the number of carbon atoms in the alkyl group of the linear alkylbenzene sulfonate is preferably 10 or more, more preferably 11 or more, and even more preferably 12 or more.
• the number of carbon atoms in the alkyl group of the linear alkylbenzenesulfonic acid is preferably 25 or less, more preferably 20 or less, and even more preferably 18 or less.
• the synergistic effect between the sulfo group salt of the compound having a sulfo group salt and the organic acid (A) and the organic acid (B) can be improved.
• the effect of inhibiting virus infection against both enveloped viruses can be improved.
• Examples of the ⁇ -olefin sulfonate include C12 to C18 sodium olefin sulfonate, C12 to C18 calcium olefin sulfonate, ammonium C12 to C18 olefin sulfonate, C12 to C18 magnesium olefin sulfonate, and C12 to C18 olefin sulfonate.
• Examples include barium olefin sulfonate, and C14 sodium tetradecene sulfonate is preferred.
• the number of carbon atoms in the ⁇ -olefin of the ⁇ -olefin sulfonate is preferably 12 or more, and preferably 14 or more.
• the number of carbon atoms in the ⁇ -olefin of the ⁇ -olefin sulfonate is preferably 22 or less, more preferably 18 or less.
• the hydrophobic moiety derived from the ⁇ -olefin chain of the compound having a salt of a sulfo group has an affinity with the organic acid (A) and the organic acid (B).
• a compound having a salt of a sulfo group approaches the organic acid (A) and an organic acid (B), and a synergistic effect between the sulfo group salt of a compound having a sulfo group salt and the organic acid (A) and the organic acid (B) can be improved, and the effect of inhibiting virus infection against both enveloped viruses and non-enveloped viruses can be improved.
• alkyldiphenyl ether sulfonates examples include sodium salts of alkyldiphenyl ether sulfonic acids with an alkyl group of C6 to C18, calcium salts of alkyldiphenyl ether sulfonic acids with an alkyl group of C6 to C18, and alkyldiphenyl ether sulfones with an alkyl group of C6 to C18.
• Examples include ammonium salts of acids, magnesium salts of alkyldiphenyl ether sulfonic acids having an alkyl group of C6 to C18, barium salts of alkyldiphenyl ether sulfonic acids having an alkyl group of C6 to C18, and sodium dodecyl diphenyl ether sulfonate having a C12 group is preferred.
• the number of carbon atoms in the alkyl group of the alkyl diphenyl ether sulfonate is preferably 8 or more, more preferably 10 or more.
• the number of carbon atoms in the alkyl group of the alkyldiphenyl ether sulfonate is preferably 24 or less, more preferably 18 or less.
• the hydrophobic moiety derived from the alkyl group of the compound having a salt of a sulfo group and the organic acid (A) and the organic acid (B) can form a salt of the sulfo group.
• the compound having the sulfo group and the organic acid (A) and the organic acid (B) come close to each other, and the synergistic effect between the sulfo group salt of the compound having the sulfo group salt and the organic acid (A) and the organic acid (B) is improved. It is possible to improve the effect of inhibiting virus infection against both enveloped viruses and non-enveloped viruses.
• the linear polymer is not particularly limited, and for example, vinyl polymer, polyester, and polyurethane are preferable, and vinyl polymer is preferable.
• the linear polymer having a salt of a sulfo group in the side chain is not particularly limited, and includes, for example, a polymer containing a styrene sulfonate component, a styrene sulfonate homopolymer, and styrene-styrene sulfonic acid.
• examples include salt copolymers, sulfonate salts of compounds obtained by sulfonating the benzene ring of polystyrene, and sulfonate salts of compounds obtained by sulfonating the benzene ring of a polymer containing a styrene component.
• the linear polymer having a sulfo group salt in its side chain is preferably a homopolymer or copolymer of a monomer having a sulfo group salt.
• monomers having a salt of a sulfo group include sodium p-styrenesulfonate, sodium m-styrenesulfonate, sodium o-styrenesulfonate, calcium p-styrenesulfonate, calcium m-styrenesulfonate, - Calcium styrene sulfonate, ammonium p-styrene sulfonate, ammonium m-styrene sulfonate, ammonium o-styrene sulfonate, sodium naphthalene sulfonate, calcium naphthalene sulfonate, etc., with sodium styrene sulfonate being preferred
• the monomer having a salt of a sulfo group may form a copolymer with other monomers.
• copolymerizable monomers include alkyl acrylate, alkyl methacrylate, vinyl alkyl ether, vinyl acetate, ethylene, propylene, butylene, butadiene, diisobutylene, vinyl chloride, vinylidene chloride, 2-vinylnaphthalene, styrene, and acrylonitrile.
• acrylic acid sodium acrylate, methacrylic acid, maleic acid, fumaric acid, maleic anhydride, acrylamide, methacrylamide, diacetone acrylamide, vinyltoluene, xylene sulfonic acid, vinylpyridine, vinyl sulfonic acid, vinyl alcohol, methyl methacrylate , sodium methacrylate, hydroxyethyl methacrylate, etc., but styrene is preferred.
• a polymer having a sulfo group salt in the side chain of a linear polymer can be produced by a general-purpose method.
• a method of radical polymerizing a monomer having a sulfo group salt A method of radical polymerizing a monomer having a sulfo group and a monomer copolymerizable with this monomer, a method in which the sulfo group of a polymer containing a monomer component having a sulfo group is removed by an alkali (e.g., sodium hydroxide, hydroxide Examples include a method of neutralizing using calcium, potassium hydroxide, ammonium hydroxide, etc.).
• an alkali e.g., sodium hydroxide, hydroxide
• Examples include a method of neutralizing using calcium, potassium hydroxide, ammonium hydroxide, etc.
• the mass ratio of the content of the compound having a sulfo group salt to the content of the organic acid (A) is preferably 1 or less, more preferably 0.7 or less, more preferably 0.6 or less, and more preferably 0.5 or less.
• the mass ratio of the content of the compound having a sulfo group salt to the content of the organic acid (A) is preferably 0.005 or more, more preferably 0.01 or more, and even more preferably 0.02 or more.
• the mass ratio of the content of the compound having a salt of a sulfo group and the content of the organic acid (A) (content of the compound having a salt of a sulfo group/content of the organic acid (A)) is 1 or less.
• the mass ratio of the content of the compound having a sulfo group salt and the content of the organic acid (A) is 0.005 or more.
• the mass ratio of the content of the compound having a sulfo group to the content of the organic acid (A) is preferably 1 or less, more preferably 0.9 or less, more preferably 0.8 or less, and more preferably 0.7 or less.
• the mass ratio of the content of the compound having a sulfo group to the content of the organic acid (A) is preferably 0.005 or more, more preferably 0.01 or more, and even more preferably 0.02 or more.
• the mass ratio of the content of the compound having a salt of a sulfo group and the content of the organic acid (A) is 1 or less.
• the mass ratio of the content of the compound having a sulfo group salt and the content of the organic acid (A) is 0.005 or more.
• the mass ratio of the content of organic acid (B) to the content of organic acid (A) (organic acid (B) content/organic acid (A) content) is preferably 2 or less, more preferably 1.6 or less, more preferably 1.2 or less, and more preferably 1 or less.
• the mass ratio of the content of organic acid (B) to the content of organic acid (A) (organic acid (B) content/organic acid (A) content) is preferably 0.1 or more, more preferably 0.2 or more, and even more preferably 0.3 or more.
• the D90 particle size of the virus infection inhibitor is more preferably 2 ⁇ m or more, more preferably 3 ⁇ m or more, and even more preferably 4 ⁇ m or more.
• the D90 particle diameter of the virus infection inhibitor is preferably 25 ⁇ m or less, more preferably 22 ⁇ m or less, and even more preferably 21 ⁇ m or less.
• the D90 particle size is 25 ⁇ m or less
• processability is improved when the virus infection inhibitor is used in a base material, and the surface area is increased to facilitate contact with the virus, so that the virus infection inhibitor can be easily contacted with the virus.
• the infection prevention effect can be improved.
• the virus infection inhibiting agent can be more uniformly adhered to the surface of the base material, and the virus infection inhibiting effect can be imparted to the base material in a more uniform state.
• the D90 particle size of the virus infection inhibitor is the particle size at which the cumulative frequency (accumulation from particles with small particle size) in the volume-based particle size distribution determined by the laser scattering method is 90% (90% cumulative particle size). diameter).
• the D90 particle size of the virus infection inhibitor is preferably 2 to 25 ⁇ m, the content of coarse particles in the virus infection inhibitor is reduced.
• virus infection inhibitor when used by incorporating the virus infection inhibitor into the base material by adjusting the D90 particle size of the virus infection inhibitor to the above range. Processability is improved, and an excellent virus infection inhibiting effect can be imparted to the base material.
• the D50 particle size of the virus infection inhibitor is preferably 0.5 ⁇ m or more, more preferably 1 ⁇ m or more, more preferably 1.5 ⁇ m or more, and more preferably 2.0 ⁇ m or more.
• the D50 particle size of the virus infection inhibitor is preferably 20 ⁇ m or less, more preferably 18 ⁇ m or less, more preferably 14 ⁇ m or less, more preferably 12 ⁇ m or less, and even more preferably 11 ⁇ m or less.
• the virus infection inhibitor by setting the D50 particle size within the above-mentioned range (preferably 0.5 to 20 ⁇ m) and the D90 particle size to 2 to 25 ⁇ m, the virus infection inhibitor has a particle size significantly different from the D50 particle size.
• the content of coarse particles having a particle size can be reduced, and the particle size of the virus infection inhibitor can be adjusted to a more appropriate size.
• the amount of functional groups present on the surface of the particulate virus infection inhibitor can be adjusted more appropriately, making it an excellent virus infection inhibitor. Provides more effective virus infection prevention effect.
• the D90 particle size and D50 particle size of the virus infection inhibitor are the particle size (90 % cumulative particle size and 50% cumulative particle size).
• the virus infection inhibitor contains an organic acid (A) (excluding compounds having a salt of a sulfo group) as an active ingredient.
• the virus infection inhibitor contains an organic acid (B) (excluding compounds having a salt of a sulfo group) as an active ingredient, if necessary.
• the virus infection inhibitor contains a compound having a sulfo group salt as an active ingredient, if necessary.
• the method for producing the virus infection inhibitor is not particularly limited.
• the virus infection inhibitor contains an organic acid (A) and a compound having a salt of a sulfo group and/or an organic acid (B)
• the compound having a salt of a sulfo group and/or the organic acid (B) (excluding compounds having a salt of a sulfo group) and an organic acid (A) (excluding a compound having a salt of a sulfo group) can be uniformly mixed in a general-purpose manner to produce a virus infection inhibitor. .
• the obtained virus infection inhibitor exhibits an excellent virus infection inhibiting effect, has an excellent virus infection inhibiting effect (antiviral property) even after wiping with water, and has excellent water resistance. .
• the virus infection inhibitor contains the organic acid (B)
• the virus infection inhibitor can immediately exhibit an excellent virus infection inhibiting effect. Furthermore, when used in a base material, an excellent virus infection inhibiting effect can be exhibited even if the base material is thick.
• the effect of inhibiting virus infection refers to the effect of eliminating or reducing the infectivity of a virus to cells, or preventing it from proliferating in cells even if infected.
• methods for confirming the presence or absence of virus infectivity include ISO 18184 and JIS L1922 for textile products, and ISO 21702 for products with plastics and non-porous surfaces other than textile products.
• the Antibacterial Products Technology Association (SIAA) certifies antiviral processing marks to products that meet the safety and certain antiviral efficacy standards for antiviral finishing agents, and the standards for antiviral efficacy are based on ISO 21702 evaluations.
• the difference (antiviral activity value) between the common logarithm value of the viral infectivity value of the blank product (product without the addition of antiviral processing agent) and the common logarithm value of the viral infectivity value of the processed product (product with addition of antiviral processing agent) It is 2.0 or more.
• Viral infection inhibitors are used as antiviral processing agents.
• the virus infection inhibitor may be used by being added to a surface coating agent such as a paint, and evaluated by the above evaluation method.
• HAU hemagglutination titer
• the difference in the common logarithm value of the virus infection titer (antiviral activity value) between the blank product and the processed product is 2.0 or more.
• the product as a viral infection inhibitor.
• the difference in the common logarithm value of the virus infectivity value (antiviral activity value) between the blank product and the processed product is 2.0 or more.
• a coating composition is prepared by supplying 30 mg of a virus infection inhibitor into 970 mg of a solvent-free ultraviolet curable acrylic resin (trade name "AI-N2" manufactured by Coattech Co., Ltd.) and mixing uniformly.
• the obtained coating composition was coated on a polyethylene film to a thickness of 18 ⁇ m using a wire bar coater #8, and then coated with a UV conveyor device Eye Grantage [manufactured by Eye Graphics Co., Ltd.
• ECS301G1 irradiator reflector: cold Using a mirror condensing type, UV lamp: H03-L31 (emission length: 365 nm), the coating composition was exposed to ultraviolet rays with an integrated light intensity of 500 mJ/cm 2 to cure the ultraviolet curable acrylic resin, and the film thickness was A coating film of 18 ⁇ m is formed and used as a test coating film (processed coating film).
• the obtained test coating film is subjected to an antiviral test in accordance with ISO21702.
• the virus infectivity titer (common logarithm value) of the test coating is calculated by the plaque method.
• a blank coating film was prepared in the same manner as above except that no virus infection inhibitor was contained, and based on this blank coating, the virus infection titer (common logarithm value) (PFU/cm 2 ) was determined in the same manner as above. Calculate.
• the virus infection value of the test coating film was calculated in the same manner as above.
• the virus infection inhibitor has a virus infection inhibiting effect against various viruses, and exhibits an excellent virus infection inhibiting effect against both enveloped viruses and non-enveloped viruses.
• enveloped viruses examples include influenza viruses (e.g., type A, type B, etc.), rubella virus, Ebola virus, coronaviruses (e.g., SARS virus, new coronavirus (SARS-CoV-2)), measles virus, varicella virus, etc.
• Herpes zoster virus herpes simplex virus, mumps virus, arbovirus, respiratory syncytial virus, hepatitis virus (e.g., hepatitis B virus, hepatitis C virus, etc.), yellow fever virus, AIDS virus, rabies virus, hantavirus, dengue virus, Nipah virus , lyssavirus, etc.
• non-enveloped viruses examples include adenovirus, norovirus, rotavirus, human papillomavirus, enterovirus, coxsackievirus, human parvovirus, encephalomyocarditis virus, poliovirus, and rhinovirus.
• the virus infection inhibitor is used while being present (for example, attached or supported) on the surface of the base particle.
• the virus infection inhibitor contains an organic acid (A) and a compound having a salt of a sulfonic acid group
• the compound having a salt of a sulfonic acid group and/or the organic acid (A) is present on the surface of the base particles ( For example, it may be used by adhering or supporting).
• the virus infection inhibitor contains an organic acid (A), an organic acid (B), and a compound having a salt of a sulfonic acid group, a compound having a salt of a sulfonic acid group, an organic acid (A), or an organic acid ( Any or all of B) may be present (for example, attached or supported) on the surface of the base particles.
• the virus infection inhibitor By allowing at least one of the active ingredients of the virus infection inhibitor to exist on the surface of the base particles, the virus infection inhibitor can be uniformly dispersed in the substrate described below without forming lumps. Therefore, the surface area of the virus infection inhibitor can be increased, sufficient contact between the virus infection inhibitor and the virus can be ensured, and the virus infection inhibiting effect of the virus infection inhibitor can be fully exhibited.
• the base particles are not particularly limited as long as they do not inhibit the virus infection inhibiting effect of the virus infection inhibitor.
• resin particles and inorganic particles are preferred.
• the synthetic resin constituting the resin particles include styrene resin, acrylic resin, urethane resin, vinyl chloride resin, ABS resin; styrene-butadiene rubber (SBR), nitrile-butadiene rubber (NBR), etc. It is preferable to include acrylic resin or styrene resin, more preferably to include styrene resin, and more preferably to include polystyrene. Note that the synthetic resins may be used alone or in combination of two or more kinds.
• the content of the acrylic resin in the resin particles is preferably 50% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, and more preferably 95% by mass or more. , 100% by mass is more preferable.
• the content of the styrene resin in the resin particles is preferably 50% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, and more preferably 95% by mass or more. , 100% by mass is more preferable.
• Styrenic resins are not particularly limited, and examples include homopolymers or copolymers containing styrene monomers as monomer units, such as styrene, methylstyrene, ethylstyrene, i-propylstyrene, dimethylstyrene, chlorostyrene, and bromostyrene. Examples include copolymers containing, as monomer units, a styrene monomer and one or more vinyl monomers copolymerizable with the styrene monomer.
• vinyl monomers copolymerizable with styrene monomers include acrylonitrile, methacrylonitrile, acrylic acid, methacrylic acid, acrylic esters (e.g., methyl acrylate, ethyl acrylate, butyl acrylate, etc.), and methacrylic esters.
• acrylic monomers such as methyl methacrylate, ethyl methacrylate, butyl methacrylate, maleic anhydride, acrylamide, and the like.
• the synthetic resin constituting the resin particles preferably contains an aromatic ring.
• the inorganic materials constituting the inorganic particles are not particularly limited, and include, for example, silica, silica gel, zeolite, hydrotalcite, calcium carbonate, calcium citrate, magnesium carbonate, magnesium hydroxide, diatomaceous earth, kaolin, talc, and water.
• the D50 particle diameter of the base particles is preferably 0.1 ⁇ m or more, more preferably 1 ⁇ m or more.
• the D50 particle diameter of the base particles is preferably 30 ⁇ m or less, more preferably 15 ⁇ m or less.
• the surface area of the base particles becomes small, the aggregation of the virus infection inhibitor is reduced, and the virus infection inhibitor becomes in a form where it is easy to interact with the virus. The infection prevention effect is improved.
• the D50 particle size of the base particles is 30 ⁇ m or less, the aggregation of the virus infection inhibitor is prevented and the surface area is increased to facilitate contact with the virus, thereby improving the virus infection inhibiting effect of the virus infection inhibitor.
• the D50 particle size of the base particles refers to the particle size (50% cumulative particle size) at which the cumulative frequency (accumulation from particles with small particle size) in the volume-based particle size distribution determined by the laser scattering method is 50%.
• the base particles include multiple types of base particles
• the D50 particle diameter of the base particles is a value measured based on the entire base particles.
• the amount of the virus infection inhibitor attached to the base particles is preferably 1 part by mass or more, more preferably 5 parts by mass or more, more preferably 7 parts by mass or more, and more preferably 10 parts by mass or more based on 100 parts by mass of the base particles. .
• the adhesion amount of the virus infection inhibitor is 1 part by mass or more, the virus infection inhibitor can be uniformly adhered to the surface of the base particles, and the virus infection inhibitory effect of the virus infection inhibitor can be more effectively exhibited. be able to.
• the amount of the virus infection inhibitor attached to the base particles is preferably 50 parts by mass or less, more preferably 40 parts by mass or less, more preferably 30 parts by mass or less, and more preferably 20 parts by mass or less based on 100 parts by mass of the base particles. .
• the adhesion amount of the virus infection inhibitor is 50 parts by mass or less, the virus infection inhibitors are not bonded to each other, and the virus infection inhibitor is efficiently disposed on the surface of the base particle, improving the virus infection inhibiting effect.
• the virus infection inhibitor the compound having a salt of a sulfonic acid group, the organic acid (A), or the organic acid (B) is attached to the surface of the base particles.
• the virus infection inhibitor is used by being included in a base material to which it is desired to impart a virus infection inhibiting effect, and the base material containing the virus infection inhibitor exhibits the virus infection inhibiting effect as a virus infection inhibiting product.
• the base material containing the virus infection inhibitor is not particularly limited as long as it can contain the virus infection inhibitor, and examples thereof include synthetic resin molded bodies such as films, paints, coatings, wallpapers, decorative sheets, and flooring materials. , textile products (woven fabrics, non-woven fabrics, knitted fabrics), interior products and interior materials for vehicles (e.g. cars, airplanes, ships, etc.) (seats, child seats and the foam materials that make them up, etc.), kitchen utensils, baby products Examples include supplies and building interior materials.
• the synthetic resin constituting the synthetic resin molded article is not particularly limited, and includes, for example, thermoplastic resins (e.g., polyethylene, polypropylene, polyvinyl chloride, polystyrene, polyvinyl acetate, polyurethane, Teflon (registered trademark), acrylonitrile butadiene styrene).
• thermoplastic resins e.g., polyethylene, polypropylene, polyvinyl chloride, polystyrene, polyvinyl acetate, polyurethane, Teflon (registered trademark), acrylonitrile butadiene styrene).
• Resin acrylonitrile styrene resin, acrylic resin, polyvinyl alcohol, polyamide, polyacetal, polycarbonate, modified polyphenylene ether, polyester, polyethylene terephthalate, polybutylene terephthalate, cyclic polyolefin, polyphenylene sulfide, polytetrafluoroethylene, polysulfone, polyether sulfone, polyarylate, polyetheretherketone, thermoplastic polyimide, polyamideimide, etc.), thermosetting resins (e.g., phenolic resins, epoxy resins, melamine resins, urea resins, unsaturated polyester resins, alkyd resins, silicone resins, polyurethanes, thermal curable polyimide, etc.).
• the synthetic resins may be used alone or in combination of two or more kinds.
• the virus infection inhibitor may be used by kneading it into a synthetic resin.
• the method for kneading the virus infection inhibitor into synthetic resin is to mix the virus infection inhibitor with the synthetic resin as a raw material to create a resin composition, and then use this resin composition to mold it using a general-purpose synthetic resin molding method.
• a virus infection inhibiting product in a desired shape can be obtained as a molded article.
• general-purpose synthetic resin molding methods include extrusion molding, injection molding, and blow molding.
• a resin composition containing a synthetic resin and a virus infection inhibitor is used as a synthetic resin molding masterbatch, and the synthetic resin molding masterbatch is mixed with the raw material synthetic resin to prevent viral infection using a general-purpose synthetic resin molding method.
• the blocking product may also be manufactured as a molded article.
• the content of the virus infection inhibitor is preferably 1 part by mass or more, more preferably 2 parts by mass or more, and even more preferably 3 parts by mass or more based on 100 parts by mass of the base material.
• the content of the virus infection inhibitor is preferably 10 parts by mass or less, more preferably 8 parts by mass or less, and more preferably 6 parts by mass or less based on 100 parts by mass of the base material.
• the ratio of the agent to the D50 particle diameter (film thickness/D50 particle diameter) is preferably 1 or more, more preferably 2 or more, and even more preferably 3 or more.
• the ratio between the thickness of the coating film (film thickness) and the D50 particle diameter of the virus infection inhibitor (film thickness/D50 particle diameter) is preferably 12 or less, more preferably 10 or less, and even more preferably 8 or less. If the ratio between the thickness of the coating film (film thickness) and the D50 particle diameter of the virus infection inhibitor (film thickness/D50 particle diameter) is 1 or more, the appearance of streaks etc.
• the coating film when processing the coating film. This is preferable because it can suppress the occurrence of defects.
• the ratio between the thickness of the coating film (film thickness) and the D50 particle diameter of the virus infection inhibitor (film thickness/D50 particle diameter) is 12 or less, the virus infection inhibitor is exposed more on the coating surface, and the coating film It is possible to impart an excellent effect of inhibiting viral infection.
• a masterbatch for synthetic resin molding contains a synthetic resin and a virus infection inhibitor. Only one type of synthetic resin may be used, or two or more types may be used in combination.
• the synthetic resin may be a thermoplastic resin or a thermosetting resin, but a thermoplastic resin is preferable.
• Thermoplastic resins include polyolefin resin, polyvinyl chloride resin, polyamide resin, polycarbonate resin, polystyrene resin, polyester resin, acrylonitrile-butadiene-styrene resin (ABS resin), polyethylene terephthalate (PET), polyurethane resin, and polymethacrylic acid. Examples include methyl (PMMA).
• the content of the synthetic resin in the masterbatch for synthetic resin molding is preferably 10% by mass or more, more preferably 20% by mass or more. preferable.
• the content of the synthetic resin in the masterbatch for synthetic resin molding is preferably 80% by mass or less, more preferably 60% by mass or less. preferable.
• the content of the virus infection inhibitor in the synthetic resin molding masterbatch is preferably 10% by mass or more, and 15% by mass or more. is more preferable.
• the content of the virus infection inhibitor in the synthetic resin molding masterbatch is preferably 80% by mass or less, and 70% by mass or less. is more preferable.
• the content of the organic acid (A) in the synthetic resin molding masterbatch is preferably 10% by mass or more, and 15% by mass. The above is more preferable.
• the content of the organic acid (A) in the synthetic resin molding masterbatch is preferably 80% by mass or less, and 70% by mass. The following are more preferred.
• the content of the organic acid (A) in the masterbatch for synthetic resin molding must be 2% by mass or more. It is preferably 3% by mass or more, and more preferably 3% by mass or more.
• the content of organic acid (A) in the masterbatch for synthetic resin molding must be 40% by mass or less. It is preferably 35% by mass or less, and more preferably 35% by mass or less.
• the content of the organic acid (B) in the masterbatch for synthetic resin molding must be 1% by mass or more.
• the virus infection inhibitor contains organic acid (A) and organic acid (B) as organic acids
• the content of organic acid (B) in the masterbatch for synthetic resin molding must be 40% by mass or less. It is preferably 35% by mass or less, more preferably 30% by mass or less, more preferably 28% by mass or less, more preferably 26% by mass or less, and even more preferably 24% by mass or less.
• the total content of organic acid (A) and organic acid (B) in the masterbatch for synthetic resin molding is preferably 10% by mass or more, more preferably 15% by mass or more.
• the total content of organic acid (A) and organic acid (B) in the masterbatch for synthetic resin molding is preferably 80% by mass or less, more preferably 70% by mass or less, more preferably 60% by mass or less, and 50% by mass or less. % or less is more preferable.
• the content of the compound having a salt of a sulfo group in the masterbatch for synthetic resin molding is more preferably 1% by mass or more, more preferably 5% by mass or more, and even more preferably 8% by mass or more.
• the content of the compound having a sulfo group salt in the master batch for synthetic resin molding is preferably 30% by mass or less, more preferably 25% by mass or less.
• the virus infection inhibitor When a virus infection inhibitor is used in a masterbatch for synthetic resin molding, the virus infection inhibitor preferably contains an organic acid (A) that is solid at 200°C under 1 atmosphere (0.101 MPa); It is more preferable to contain an organic acid (A) that is solid at 210°C under 0.101 MPa), and more preferably to contain an organic acid (A) that is solid at 220°C under 1 atm (0.101 MPa). .
• the virus infection inhibitor When a virus infection inhibitor is used in a masterbatch for synthetic resin molding, the virus infection inhibitor preferably contains an organic acid (B) that is solid at 190°C under 1 atmosphere (0.101 MPa); It is more preferable to contain an organic acid (B) that is solid at 200°C under 0.101 MPa), and more preferably to contain an organic acid (B) that is solid at 220°C under 1 atm (0.101 MPa). .
• the synthetic resin molding masterbatch may be heated and melted. When it is included, deterioration of the virus infection inhibitor and discoloration of the resulting molded product can be easily suppressed.
• Examples of the above organic acids (A) include alginic acid (melting point 300°C under 1 atmosphere (0.101 MPa)), isophthalic acid (melting point 345°C under 1 atmosphere (0.101 MPa)), terephthalic acid (melting point 345°C under 1 atmosphere (0.101 MPa)), 1 atm (0.101 MPa), melting point 300° C.), etc.
• Examples of the above-mentioned organic acids (B) include 1,3-diaminopropanetetraacetic acid (melting point (thermal decomposition temperature) 237°C at 1 atm (0.101 MPa)), phthalic acid (at 1 atm (0.101 MPa), melting point (thermal decomposition temperature) 237°C); 101 MPa), melting point 191°C), etc.
• the resin composition especially the masterbatch for synthetic resin molding, further contains a surfactant.
• the surfactant is not particularly limited, and includes, for example, anionic surfactants (excluding anionic surfactants containing sulfo group salts), cationic surfactants, nonionic surfactants, and amphoteric surfactants. Examples include surfactants, and anionic surfactants and nonionic surfactants are preferred.
• anionic surfactants include, but are not limited to, alkyl phosphates such as sodium dodecyl phosphate, potassium dodecyl phosphate, sodium stearyl phosphate, and potassium stearyl phosphate, and polyoxyethylene (3) lauryl ether phosphate.
• alkyl phosphates such as sodium dodecyl phosphate, potassium dodecyl phosphate, sodium stearyl phosphate, and potassium stearyl phosphate
• polyoxyethylene (3) lauryl ether phosphate such as sodium dodecyl phosphate, potassium dodecyl phosphate, sodium stearyl phosphate, and potassium stearyl phosphate
• polyoxyethylene (3) lauryl ether phosphate such as sodium dodecyl phosphate, potassium dodecyl phosphate, sodium stearyl phosphate, and potassium stearyl phosphate
• polyoxyethylene (3) lauryl ether phosphate such as sodium dodecyl
• Nonionic surfactants are not particularly limited, and include, for example, polyoxyalkylene alkyl ether, polyoxyethylene alkyl ether, polyoxyethylene alkyl phenyl ether, polyoxyethylene fatty acid ester (for example, polyethylene glycol distearate, etc.), and sorbitan.
• Fatty acid ester polyoxyethylene sorbitan fatty acid ester, polyoxyethylene sorbitol fatty acid ester, glycerin fatty acid ester, polyoxyethylene glycerin fatty acid ester, polyglycerin fatty acid ester, sucrose fatty acid ester, polyoxyethylene alkylamine, polyoxyethylene fatty acid amide, Examples include fatty acid alkylolamides, alkyl alkanolamides, acetylene glycol, oxyethylene adducts of acetylene glycol, polyethylene glycol polypropylene glycol block copolymers, and polyoxyethylene fatty acid esters are preferred.
• amphoteric surfactant is not particularly limited and includes, for example, alkylaminoacetate betaine, alkylamidopropyl betaine, sulfobetaine, alkylamino (mono- or di)propionate, imidazolinium betaine, alkylamine oxide, alkylaminoethyl Glycine, alkyldi(aminoethyl)glycine, glycine n-(3-aminopropyl) C10-16 derivative, alkylpolyaminoethylglycine, alkyl ⁇ -alanine, alkyldiethanolamine, polyoxyalkylenealkylamine, oxyethylene-added surfactant of diamine Examples include.
• the content of the surfactant in the resin composition is preferably 0.1% by mass or more, more preferably 1% by mass or more.
• the content of the surfactant in the resin composition is preferably 40% by mass or less, more preferably 30% by mass or less.
• the mass ratio of the surfactant content to the organic acid (A) content is preferably 0.05 or more, more preferably 0.1 or more, and even more preferably 0.2 or more.
• the mass ratio of the surfactant content to the organic acid (A) content is preferably 1 or less, more preferably 0.5 or less, more preferably 0.4 or less, and more preferably 0.3 or less.
• the mass ratio of the surfactant content to the organic acid (A) content is within the above range, viral infection may occur. It is easy to increase the water resistance of prevention products (molded products).
• the total content of the organic acid (A) and the organic acid (B) is preferably 0.05 or more, more preferably 0.1 or more, More preferably 0.2 or more.
• the mass ratio of the surfactant content to the total content of the organic acid (A) and the organic acid (B) is preferably 1 or less, more preferably 0.5 or less, more preferably 0.4 or less, and more preferably 0.3 or less.
• the mass ratio of the surfactant content to the total content of the organic acid (A) and the organic acid (B) (surfactant content/organic acid (A) and organic acid (B) content)
• the total content (total content) is within the above range, the water resistance of the virus infection inhibiting product (molded article) can be easily improved, and the virus infection inhibiting effect of the virus infection inhibiting agent can be immediately expressed.
• the masterbatch for synthetic resin molding is preferably a resin pellet because it has excellent moldability. By melting and molding resin pellets, it is possible to obtain a virus infection prevention product (molded article) with excellent virus infection prevention effects.
• the shape of the resin pellet is not particularly limited, and examples include spherical, cylindrical, and prismatic shapes. From the viewpoint of stability of the pellet shape, a cylindrical shape is preferable.
• the maximum length dimension of the resin pellet is preferably 1 mm or more, more preferably 3 mm or more.
• the maximum length dimension of the resin pellet is preferably 10 mm or less, more preferably 7 mm or less.
• the masterbatch for synthetic resin molding can be used by mixing it with other resin materials.
• the other resin material may be resin pellets. After mixing the synthetic resin molding masterbatch and the other resin materials to obtain a mixed resin material, the mixed resin material is molded to produce a virus infection prevention product (molded products) can be obtained.
• paint conventionally known paints are used, such as oil-based paints (for example, blended paints, oil varnishes, etc.), cellulose paints, synthetic resin paints, and the like.
• the paint may contain additives such as pigments, plasticizers, curing agents, extenders, fillers, anti-aging agents, thickeners, surfactants, etc. within the range that does not impair its physical properties.
• a method of incorporating the virus infection inhibitor into the paint for example, a method of supplying the virus infection inhibitor and the paint to a dispersion device and uniformly mixing them can be mentioned.
• the dispersion device include a high-speed mill, a ball mill, and a sand mill.
• Architectural interior materials are not particularly limited, and include, for example, flooring materials, wallpaper, ceiling materials, paints, doorknobs, switches, switch covers, wax, and the like.
• Vehicle interior supplies and vehicle interior materials are not particularly limited, and include, for example, seats, child seats, seat belts, car mats, seat covers, doors, ceiling materials, floor mats, door trims, instrument panels, consoles, glove boxes, hanging leather, handrails, etc. can be mentioned.
• the polyacrylic acid solution was heated to 120° C. for 90 minutes to crosslink the polyacrylic acid and dry it to obtain crosslinked polyacrylic acid.
• the gel fraction of crosslinked polyacrylic acid 1 was 85.4% by mass.
• the gel fraction of crosslinked polyacrylic acid 2 was 99.5% by mass.
• a particulate virus infection inhibitor was prepared by uniformly mixing a compound having a salt of a sulfo group (salt compound), an organic acid (A), and an organic acid (B) shown in Table 2.
• Table 3 shows the contents of the compound having a salt of a sulfo group (salt compound), the organic acid (A), and the organic acid (B) in the virus infection inhibitor.
• the mass ratio of the content of the compound having a salt of a sulfonic acid group and the content of the organic acid (A) are shown in Table 3.
• Table 3 shows the mass ratio between the content of organic acid (B) and the content of organic acid (A) (content of organic acid (B)/content of organic acid (A)) in the virus infection inhibitor. Indicated.
• a compound having a salt of a sulfo group was written as a "salt compound”.
• the mass ratio between the content of the compound having a salt of a sulfonic acid group and the content of the organic acid (A) is calculated as follows: /Organic acid (A)".
• the mass ratio between the content of organic acid (B) and the content of organic acid (A) (content of organic acid (B)/content of organic acid (A)) is "organic acid (B)/organic acid (A) content”. It was written as "acid (A)".
• melting point under 1 atm (1013.25 hPa) "solubility in water at 25°C” and “pKa1 at 25°C” are simply “melting point”, “solubility” and “pKa1”, respectively.
• thermal decomposition temperature is listed instead of melting point.
• fumaric acid the “sublimation temperature” is listed instead of the melting point. If the “melting point” and “molecular weight” in the table could not be measured, it was written as “unmeasurable.” For 1,3-diaminopropanetetraacetic acid, the "thermal decomposition temperature” was written instead of the melting point.
• “>Z" Z is a numerical value) means larger than Z.
• Table 3 shows the D50 particle diameter ( ⁇ m) and D90 particle diameter ( ⁇ m) of the obtained virus infection inhibitor.
• the obtained virus infection inhibitor was subjected to an antiviral test using influenza virus (enveloped virus) and/or feline calicivirus (non-enveloped virus), and the results are shown in Table 4.
• a coating composition was prepared by mixing 3 parts by mass of a virus infection inhibitor and 97 parts by mass of an ultraviolet curable acrylic paint (trade name "AI-N2", manufactured by Coattech Co., Ltd.). The coating composition was applied onto a polyethylene film to a thickness of 18 ⁇ m using a wire bar coater #8 to form a coating layer.
• AI-N2 ultraviolet curable acrylic paint
• the UV-curable acrylic paint was cured by irradiating the coating layer with ultraviolet rays with a wavelength of 365 nm at a cumulative light intensity of 500 mJ/cm 2 at 25°C using a UV conveyor device (“ECS301G1” manufactured by Eye Graphics).
• a test coating film having a thickness of 18 ⁇ m was formed.
• the antiviral test of the obtained test coating film was conducted in accordance with ISO21702.
• the virus infectivity titer common logarithm value
• a blank coating film was prepared in the same manner as above except that no virus infection inhibitor was contained, and based on this blank coating, the virus infection titer (common logarithm value) (PFU/cm 2 ) was determined in the same manner as above. was calculated.
• the virus infectivity titer (common logarithmic value) of the blank coating film was 6.5 PFU/cm 2 .
• the antiviral activity value (initial activity value) was calculated by subtracting the virus infection titer of the test coating from the virus infection titer of the blank coating.
• a coating composition was prepared by mixing 3 parts by mass of a virus infection inhibitor and 97 parts by mass of an ultraviolet curable acrylic paint (trade name "AI-N2", manufactured by Coattech Co., Ltd.). The coating composition was applied onto a polyethylene film to a thickness of 18 ⁇ m using a wire bar coater #8 to form a coating layer.
• AI-N2 ultraviolet curable acrylic paint
• the UV-curable acrylic paint was cured by irradiating the coating layer with ultraviolet rays with a wavelength of 365 nm at a cumulative light intensity of 500 mJ/cm 2 at 25°C using a UV conveyor device (“ECS301G1” manufactured by Eye Graphics). A coating film having a thickness of 18 ⁇ m was formed.
• a water resistance test was conducted on the obtained coating film in accordance with the Water Resistance Class 1 water resistance test specified by SIAA.
• the antiviral test was carried out in the same manner as the initial activity value, except that the water adhering to the surface of the coating film after the water resistance test was removed by absorbing it with a cloth.
• the activity value [activity value after water resistance test (18 ⁇ m)] was calculated.
• the antiviral activity value was measured in the same manner as the initial activity value, except that the virus infectivity value (common logarithm value) of the test coating was calculated by the plaque method. (immediate activity value) was calculated.
• the virus infectivity titer (common logarithm value) of the blank coating film was 6.5 PFU/cm 2 .
• a coating composition was prepared by mixing 3 parts by mass of a virus infection inhibitor and 97 parts by mass of an ultraviolet curable acrylic paint (trade name "AI-N2", manufactured by Coattech Co., Ltd.). The coating composition was applied onto a polyethylene film to a thickness of 18 ⁇ m using a wire bar coater #8 to form a coating layer.
• AI-N2 ultraviolet curable acrylic paint
• the UV-curable acrylic paint was cured by irradiating the coating layer with ultraviolet rays with a wavelength of 365 nm at a cumulative light intensity of 500 mJ/cm 2 at 25°C using a UV conveyor device (“ECS301G1” manufactured by Eye Graphics). A coating film having a thickness of 18 ⁇ m was formed.
• a square cotton cloth with a side of 6 cm [attached white cloth for JIS L0803 compliant test cotton (Kanakin No. 3)] is impregnated with 0.5 mL of 0.05% by mass sodium hypochlorite aqueous solution (25°C), A cotton cloth was attached to the friction element of a friction tester type I (manufactured by Imoto Seisakusho Co., Ltd.). After rubbing the surface of the obtained coating film 400 times at a pressure of 40 g/cm 2 , the surface of the coating film was washed with a neutral detergent. The coating was dried at room temperature to provide a test coating. The cotton cloth was replaced with a new cotton cloth impregnated with 0.05% by mass aqueous sodium hypochlorite solution every 100 times.
• the obtained test coating was subjected to an antiviral test in the same manner as the initial activity value, and the antiviral activity value (activity value after Na hypochlorite treatment) was calculated.
• test coating was prepared in the same manner as when measuring the initial activity value.
• the resulting test coating was evaluated for whitening properties in accordance with JIS A 1454 Test Methods for Polymer Flooring Materials: Stain Resistance Test.
• JIS A 1454 Test Methods for Polymer Flooring Materials Stain Resistance Test.
• 2 mL of purified water was dropped onto the surface of the test coating film, covered with a watch glass, and allowed to stand for 24 hours. Thereafter, it was removed with a household neutral detergent, and the surface of the test coating was further wiped with industrial alcohol, and left to stand for 1 hour in a testing room.
• the haze of the test coating film was evaluated in accordance with JIS K 7361.
• the haze value (%) was measured using a haze meter (trade name: HM-150, manufactured by Murakami Color Research Institute) at a room temperature of 25° C. and a relative humidity of 40%.
• HM-150 manufactured by Murakami Color Research Institute
• Example 6 [Masterbatch for synthetic resin molding] (Examples 26 to 34, Comparative Example 6) A particulate virus infection inhibitor was prepared by uniformly mixing a compound having a salt of a sulfo group (salt compound), an organic acid (A), and an organic acid (B) shown in Table 6. Table 7 shows the contents of the compound having a salt of a sulfo group (salt compound), the organic acid (A), and the organic acid (B) in the virus infection inhibitor.
• the mass ratio of the content of the compound having a salt of a sulfonic acid group and the content of the organic acid (A) are shown in Table 7.
• Table 7 shows the mass ratio between the content of organic acid (B) and the content of organic acid (A) (content of organic acid (B)/content of organic acid (A)) in the virus infection inhibitor. Indicated.
• Table 7 shows the D50 particle diameter ( ⁇ m) and D90 particle diameter ( ⁇ m) of the obtained virus infection inhibitor.
• Example 28 60 parts by mass of the obtained virus infection inhibitor and 40 parts by mass of polypropylene (manufactured by Japan Polypropylene Co., Ltd., trade name "Novatec PP BC6C") as a synthetic resin were mixed, and a synthetic resin molding master was prepared. A batch was made.
• polypropylene manufactured by Japan Polypropylene Co., Ltd., trade name "Novatec PP BC6C”
• the obtained synthetic resin molding masterbatch and separately prepared polypropylene (manufactured by Nippon Polypro Co., Ltd., trade name "Novatec PP BC6C”) were combined. They were mixed at a blending ratio of 1:9 (mass ratio) and kneaded at 180°C for 5 minutes. Next, the obtained resin composition was press-molded to obtain a sheet-like resin molded product (average thickness 1 mm, content of virus infection inhibitor: 5% by mass) as a virus infection prevention product.
• the initial activity value, the activity value after the water resistance test, and the immediate activity value were measured using the same test method as for the above-mentioned coating film, and the results are shown in Table 9.
• the activity value after the water resistance test was written in the column "Activity value after the water resistance test (1 mm)".
• a sheet-shaped resin molded product was used instead of the test coating, and a blank sheet-shaped resin molded product using polypropylene (manufactured by Nippon Polypropylene Co., Ltd., product name "Novatec PP BC6C”) (no surfactant used) was used.
• a molded article (blank sheet) was produced, and the initial activity value, the activity value after the water resistance test, and the immediate activity value were measured in the same manner as described above, except that the blank sheet was used instead of the blank coating film.
• the virus infection inhibitor of the present invention contains an organic acid (A) having a solubility in water at 25°C of 0.4 g/L or less, it can maintain an excellent virus infection inhibiting effect even after wiping with water. .
• Viral infection inhibitors have excellent virus infection inhibiting effects against both enveloped viruses and non-enveloped viruses, and exhibit virus infection inhibiting effects against various types of viruses.
• virus infection inhibitor of the present invention By incorporating the virus infection inhibitor of the present invention into a base material, an excellent virus infection inhibiting effect can be imparted to the base material.

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Pest Control & Pesticides (AREA)
• Plant Pathology (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Environmental Sciences (AREA)
• Dentistry (AREA)
• Agronomy & Crop Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• Polymers & Plastics (AREA)
• General Chemical & Material Sciences (AREA)
• Toxicology (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (3)

Applications Claiming Priority (6)

Publications (1)

Family

ID=90191171

Family Applications (1)

Country Status (5)

Cited By (1)

Citations (6)

Family Cites Families (5)

• 2023
  • 2023-09-05 WO PCT/JP2023/032434 patent/WO2024053654A1/ja not_active Ceased
  • 2023-09-05 KR KR1020257009950A patent/KR20250058025A/ko active Pending
  • 2023-09-05 JP JP2023564460A patent/JP7818017B2/ja active Active
  • 2023-09-05 CN CN202380063794.3A patent/CN119836231A/zh active Pending
  • 2023-09-06 TW TW112133900A patent/TW202425810A/zh unknown

Patent Citations (6)

Also Published As

Similar Documents

Legal Events